EQ 302
Alternative Names: EQ-302Latest Information Update: 23 Sep 2024
At a glance
- Originator Equillium
- Class Anti-inflammatories; Peptides
- Mechanism of Action Interleukin 15 inhibitors; Interleukin 21 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Gastrointestinal disorders
Most Recent Events
- 16 Sep 2024 Vivtex and Equillium enters into R&D agreement to develop GI-targeted formulations for EQ 302
- 08 Aug 2024 Equillium plans a phase I trial for Gastrointestinal disorders in the second half of 2025 (PO)
- 21 Dec 2023 Pharmacodynamics data from a preclinical trial in Gastrointestinal disorders released by Equillium